Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancerReid T. Powell, Helen Piwnica‐Worms, Abena B. Redwood et al.|Scientific Reports|2020Cited by 22
Targeting neddylation and sumoylation in chemoresistant triple negative breast cancerReid T. Powell, Helen Piwnica‐Worms, Amanda L. Rinkenbaugh et al.|npj Breast Cancer|2024Cited by 11
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant ChemotherapyAmanda L. Rinkenbaugh, Helen Piwnica‐Worms, Faiza Baameur et al.|Cancer Research|2025Cited by 2
Abstract 6620: PDX models of TNBC established from pre- and post-therapy tumors identify vulnerabilities of resistant diseaseAmanda L. Rinkenbaugh, Helen Piwnica‐Worms, Yuan Qi et al.|Cancer Research|2024Cited by 1
Supplementary Figure S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant ChemotherapyAmanda L. Rinkenbaugh, Helen Piwnica‐Worms, Yuan Qi et al.|Unknown|2025Cited by 0